Drug-induced long QT syndrome and drug development

British Journal of Clinical Pharmacology

Volumn 66, Issue 3, 2008, Pages 341-344

  Ritter, J M ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; CYTOCHROME P450 INHIBITOR; DIGOXIN; LAMOTRIGINE; MOXIFLOXACIN; STROPHANTHIN;

DRUG DEVELOPMENT; DRUG SAFETY; EDITORIAL; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; QT INTERVAL; SIDE EFFECT;

ELECTROCARDIOGRAPHY; HUMANS; LONG QT SYNDROME; TORSADES DE POINTES;

EID: 49549091129     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03275.x     Document Type: Editorial

References (18)

1. Novo G, Guttilla D, Fazio G, Cooper D, Novo S. The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBs. Br J Clin Pharmacol 2008 66 : 345 51.
2. Gupta A, Badyal DK, Khosla PP, Uppal B, Jaison TM, Chopra S. Effect of atorvastatin on hs-CRP in acute coronary syndrome. Br J Clin Pharmacol 2008 66 : 411 3.
3. Iida S. Population pharmacokinetic and pharmacodynamic modeling of the effects of nicorandil in the treatment of acute heart failure. Br J Clin Pharmacol 2008 66 : 352 65.
4. Mirdamadi HZ, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol 2008 66 : 366 74.
5. Molokhia M, Pathak A, Lapeyre-Mestre M, Pharm LC, Montastruc JL, L'Association française des centres régionaux de pharmacovigilance (CRPV), McKeigue P. Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France. Br J Clin Pharmacol 2008 66 : 386 95.
6. Dixon R, Job S, Oliver R, Tompson D, Wright JG, Maltby K, Lorch U, Taubel J. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol 2008 66 : 396 404.
7. Hennessy S, Leonard CE, Newcomb C, Kimmel SE, Bilker WB. Cisapride and ventricular arrhythmia. Br J Clin Pharmacol 2008 66 : 375 85.
8. Mines GR. On circulating excitations in heart muscle and their possible relation to tachycardia and fibrillation. Trans R Soc Canada 1914 8 : 43 52.
9. DeSilva RA. George Ralph Mines, ventricular fibrillation and the discovery of the vulnerable period. JACC 1997 29 : 1397 402.
10. Welsh MJ, Hoshi T. Molecular cardiology - ion channels lose the rhythm. Nature 1995 376 : 640 1.
11. Waldo AL, Camm AJ, de Ruyder H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996 348 : 7 12.
12. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effects of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989 321 : 406 12.
13. Ritter JM. Chronic disease: when in doubt, consider accrual into a randomised controlled trial (RCT). Br J Clin Pharmacol 2008 66 : 169 72.
14. Roden DM, Lazzara R, Rosen M et al. Multiple mechanisms in the long-QT syndrome. Circulation 1996 94 : 1996 2012.
15. Mitcheson JS, Chen J, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. PNAS 2000 97 : 12329 33 (see also commentary on this paper by Kass RS and Cabo C Channel structure and drug-induced cardiac arrhythmias PNAS 2000; 07: 11683-4).
16. ICH guideline S7B. Safety pharmacology studies for assessing the potential for delayed ventricular repolarisation (QT interval prolongation) by human pharmaceuticals. Available at http://www.ich.org
17. Rang HP. Assessing drug safety. In Drug discovery and development. Technology in transition HP Rang (ed). Ch 16. Edinburgh : Churchill Livingstone, Elsevier, 2006 : 229 42.
18. Altman LK. Who Goes First?: The Story of Self-Experimentation in Medicine. Random House, 1987.